上气道手术与阻塞性睡眠呼吸暂停患者心血管生物标志物改善及风险的相关性
研究纳入161例新诊断的阻塞性睡眠呼吸暂停(OSA)患者,接受经典或改良悬雍垂腭咽成形术伴或不伴颏舌肌前移和舌骨悬吊,比较术前与术后至少6个月的评估。结果显示术后呼吸暂停低通气指数、年龄校正Framingham风险评分及多项心血管代谢生物标志物显著下降,术前存在代谢异常的患者术后风险改善更明显。
要点
- OSA上气道手术与心血管代谢生物标志物水平及整体心血管风险改善相关。
- 术前存在代谢异常的患者术后风险改善更明显(P < 0.001)。
- 生物标志物变化可能与术后夜间氧饱和度改善相关。
核心结论
- OSA相关上气道手术与心血管代谢生物标志物水平及整体心血管风险改善相关,尤其在同时患有OSA和代谢紊乱的患者中。
- 生物标志物水平的变化可能与术后氧饱和度改善相关。
研究设计与样本
- 纳入161例新诊断的OSA患者,接受经典或改良悬雍垂腭咽成形术伴或不伴颏舌肌前移和舌骨悬吊。
- 比较术前与术后至少6个月的评估,包括多导睡眠监测、血糖和血脂测定、血压及整体心血管风险(通过Framingham风险评分估计)。
- 采用Benjamini-Hochberg校正进行多重比较。
主要发现
- 平均随访时间为2.5 ± 1.9年。
- 整个队列呼吸暂停低通气指数显著下降,平均变化(95%置信区间)为-25.3(-29.5,-21.0)次/小时,P < 0.001。
- 年龄校正Framingham风险评分下降-2.5%(-4.0%,-1.0%),P < 0.001。
- 术后血糖下降-0.50(-0.70,-0.30)mmol/L,P < 0.001;总胆固醇下降-0.46(-0.65,-0.28)mmol/L,P < 0.001;甘油三酯下降-0.56(-0.99,-0.14)mmol/L,P = 0.014;低密度脂蛋白胆固醇下降-0.27(-0.43,-0.11)mmol/L,P = 0.002;载脂蛋白B下降-0.10(-0.14,-0.07)g/L,P < 0.001;收缩压下降-3.58(-6.02,-1.14)mmHg,P = 0.007;舒张压下降-3.25(-5.47,-1.02)mmHg,P = 0.008。
- 术前存在代谢异常的患者术后风险特征变化更好(P < 0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate the association between upper airway surgery and changes of cardiological metabolic biomarkers and the overall cardiovascular risk in obstructive sleep apnea (OSA), and to define factors associated with better cardiovascular outcomes. METHODS: A total of 161 patients with newly diagnosed OSA who underwent classical or modified uvulopalatopharyngoplasty with or without genioglossus advancement and hyoid suspension were included. The pre- and postoperative (at least 6 months later) assessments, including polysomnography, measurement of glucose and lipids, blood pressure, and overall cardiovascular risk (as estimated by Framingham Risk Scores), were compared. We accounted for multiple comparisons with the use of the Benjamini-Hochberg correction. RESULTS: The mean follow-up time was 2.5 ± 1.9 years. The apnea hypopnea index decreased significantly in the entire cohort (mean changes with 95% confidence intervals were [-25.3 (-29.5, -21.0) events/hour, P < 0.001]. We also noted decreases in the age-adjusted Framingham Risk Scores [-2.5% (-4.0%, -1.0%), P < 0.001] as well as single cardiometabolic biomarkers, including glucose [-0.50 (-0.70, -0.30) mmol/L, P < 0.001], total cholesterol [-0.46 (-0.65, -0.28) mmol/L, P < 0.001], triglycerides [-0.56, (-0.99, -0.14) mmol/L, P = 0.014], low-density lipoprotein cholesterol [-0.27, (-0.43, -0.11) mmol/L, P = 0.002], apolipoprotein B [-0.10 (-0.14, -0.07) g/L, P < 0.001], systolic blood pressure [-3.58 (-6.02, -1.14) mmHg, P = 0.007], and diastolic blood pressure [-3.25 (-5.47, -1.02) mmHg, P = 0.008] after surgery. Patients with preoperative metabolic abnormalities exhibited better postoperative risk profiles changes (P < 0.001). In addition, associations were found between Δapolipoprotein B, Δsystolic blood pressure, and improvements in nocturnal oxygen level after surgery. CONCLUSION: OSA-related upper airway surgery was associated with improvements in cardiological metabolic biomarker levels and the overall cardiovascular risk, especially in patients with both OSA and metabolic disorders. The changes in biomarker levels may be associated with improved oxygen saturation after surgery. LEVEL OF EVIDENCE: 4 Laryngoscope, 130:818-824, 2020.
引用
- Qian Y, Zou J, Xu H, et al. Association of upper airway surgery and improved cardiovascular biomarkers and risk in OSA. Laryngoscope. 2019. PMID: 31077395. doi:10.1002/lary.28012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。